E.SongH
Related guides Does Blue Cross Blue Shield Cover GLP-1 Medications for Weight Loss and Diabetes
34 The FOCUS Trial should shed light on how many patients treated with GLP-1/GIP agonists experience significant worsening of their DR and macular edema
Chak Kwong Cheng, [email protected] These authors have contributed equally to this work and share first authorship Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Most will see some redness and warmth from injection on areas of the body that have been treated but subsided in time
however, no impact on other pro-inflammatory markers, including C-reactive protein (CRP), IL-6, IL-17, or immunoglobulin antibodies, was observed